

Alison L Allan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2559318/publications.pdf>

Version: 2024-02-01

42
papers

3,038
citations

257450

24
h-index

276875

41
g-index

44
all docs

44
docs citations

44
times ranked

5135
citing authors

#	ARTICLE	IF	CITATIONS
1	High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2236-2252.	3.6	451
2	The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells. <i>Stem Cell Reviews and Reports</i> , 2011, 7, 292-306.	5.6	442
3	Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 75-87.	2.5	265
4	Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic. <i>Journal of Oncology</i> , 2010, 2010, 1-10.	1.3	170
5	Stereotactic ablative radiotherapy for the comprehensive treatment of 4â€“10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. <i>BMC Cancer</i> , 2019, 19, 816.	2.6	165
6	Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2272.	4.1	143
7	Tumor Dormancy and Cancer Stem Cells: Implications for the Biology and Treatment of Breast Cancer Metastasis. <i>Breast Disease</i> , 2007, 26, 87-98.	0.8	139
8	Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 128, 156-169.	4.3	124
9	Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. <i>Journal of Cellular Biochemistry</i> , 2007, 102, 859-868.	2.6	120
10	Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 97-113.	3.3	108
11	Role of the Integrin-Binding Protein Osteopontin in Lymphatic Metastasis of Breast Cancer. <i>American Journal of Pathology</i> , 2006, 169, 233-246.	3.8	94
12	Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. <i>Molecular Cancer Research</i> , 2003, 1, 810-9.	3.4	76
13	Stereotactic ablative radiotherapy for the comprehensive treatment of 1â€“3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. <i>BMC Cancer</i> , 2020, 20, 380.	2.6	75
14	Differential Functional Roles of ALDH1A1 and ALDH1A3 in Mediating Metastatic Behavior and Therapy Resistance of Human Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2039.	4.1	70
15	Recent Advances in the Molecular Characterization of Circulating Tumor Cells. <i>Cancers</i> , 2014, 6, 595-624.	3.7	56
16	The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 243-254.	2.5	51
17	Magnetically Guided Self-Assembled Protein Micelles for Enhanced Delivery of Dasatinib to Human Triple-Negative Breast Cancer Cells. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1713-1725.	3.3	47
18	Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2009, 75A, 344-355.	1.5	46

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition. <i>Advances in Clinical Chemistry</i> , 2018, 83, 121-181.	3.7	35
20	Soluble bone-derived osteopontin promotes migration and stem-like behavior of breast cancer cells. <i>PLoS ONE</i> , 2017, 12, e0177640.	2.5	33
21	Lung-Derived Factors Mediate Breast Cancer Cell Migration through CD44 Receptor-Ligand Interactions in a Novel Ex Vivo System for Analysis of Organ-Specific Soluble Proteins. <i>Neoplasia</i> , 2014, 16, 180-W27.	5.3	31
22	Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer. <i>Oncotarget</i> , 2016, 7, 76125-76139.	1.8	29
23	User-defined protein marker assay development for characterization of circulating tumor cells using the CellSearch [®] system. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 983-995.	1.5	26
24	Role of the Microenvironment in Regulating Normal and Cancer Stem Cell Activity: Implications for Breast Cancer Progression and Therapy Response. <i>Cancers</i> , 2019, 11, 1240.	3.7	23
25	Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. <i>Cytometry Part B - Clinical Cytometry</i> , 2009, 76B, 107-117.	1.5	22
26	Circulating Tumor Cell Analysis in Preclinical Mouse Models of Metastasis. <i>Diagnostics</i> , 2018, 8, 30.	2.6	22
27	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. <i>Oncotarget</i> , 2018, 9, 8155-8164.	1.8	18
28	EMT-independent detection of circulating tumor cells in human blood samples and pre-clinical mouse models of metastasis. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 97-108.	3.3	16
29	On-Chip Preparation of Amphiphilic Nanomicelles ^{“in”} Sodium Alginate Spheroids as a Novel Platform Against Triple-Negative Human Breast Cancer Cells: Fabrication, Study of Microfluidics Flow Hydrodynamics and Proof of Concept for Anticancer and Drug Delivery Applications. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3528-3539.	3.3	11
30	Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications. <i>Journal of Visualized Experiments</i> , 2014, , e51248.	0.3	9
31	A survivin-driven, tumor-activatable minicircle system for prostate cancer theranostics. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 209-219.	4.4	9
32	Reduced Zeb1 Expression in Prostate Cancer Cells Leads to an Aggressive Partial-EMT Phenotype Associated with Altered Global Methylation Patterns. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12840.	4.1	9
33	Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study. <i>Lung Cancer</i> , 2022, 165, 145-151.	2.0	6
34	Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 273-273.	1.6	5
35	Lung-Derived Selectins Enhance Metastatic Behavior of Triple Negative Breast Cancer Cells. <i>Biomedicines</i> , 2021, 9, 1580.	3.2	5
36	NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5042-5042.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	2
38	Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5075-5075.	1.6	2
39	Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: A first-in-human pilot study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3530-3530.	1.6	2
40	Response to Rossi et al.. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83A, 599-601.	1.5	0
41	Recombinant Human Erythropoietin (rHuEPO) In Combination with Chemotherapy Increases Breast Cancer Metastasis In Pre-Clinical Mouse Models. <i>Blood</i> , 2010, 116, 3345-3345.	1.4	0
42	Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	0